AARTIDRUGS

Pharmaceuticals & Drugs

₹485.6

0.00 (0.00%)

Market Cap	4,463 Cr		EPS	19.6		High	498.4
Stock P/E	24.8		Net Profit Margin	6.2		Low	485

The current prices are delayed, login to your account to see live prices.

Performance

Today’s Low

Today’s High

485

498.4

52W Low

52W High

313.9

625

Open Price	490.3	Volume	60
Prev. Close	487.7

Fundamentals

Market Cap	4,463 Cr	ROE	14.9%
P/E Ratio(TTM)	24.8	EPS(TTM)	0.0
P/B Ratio	3.7	Dividend Yield	0.2%
Industry P/E	40.5	Book Value	131.6
		Face Value	10.0

About the Company

Aarti Drugs Ltd. was established in the year 1984 and forms part of $900 Million Aarti Group of Industries with robust R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC) in close vicinity to manufacturing locations.

Over the years, the Company has been able to carve a niche for itself and is looking forward to expand the volumes. With the government initiative to encourage private health insurance schemes, consumer spending on medicines is expected to increase, which will spur growth in the generic sector in the domestic market.

The manufacturing-units of Aarti Drugs Ltd. are GMP certified. The Company is also in the process of acquiring an ISO 9002 compliance for all its units and one of the units has already been approved.

The Company aims at becoming the first choice of this expanding market through better products, ensuring quality and timely delivery.

Business area of the company

The company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and also produces Formulations with its wholly-owned subsidiary - Pinnacle Life Science Private Limited.

Products under APIs includes Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole, Ofloxacin etc. whereas Specialty Chemicals includes Benzene Sulphonyl Chloride, Methyl Nicotinate etc.

Awards and accolades

1991-1992: Outstanding Performance in Export from Chemexcil
2001: Best Vendor from Organization of Pharmaceutical Product
2005: Customer Responsiveness from Avaya Global Connect
2013: Business Partner of the year from Abbott
2014: Appreciation as business partner from Abbott
2014: Certificate of Recognition - Star Export House from Government of India (Ministry of Commerce and Industry)
2015: Business Partner of the year from Abbott
2006: Customer Responsiveness from Avaya Global Connect
2016: Business Partner of the year from Abbott
2016: Outstanding Performance in Export from Pharmexcil
2017: Business Partner of the year from Abbott
2017: Outstanding Performance Latin American Export from Pharmexcil
2018: Business Partner of the year from Abbott

Milestones

1984: Incorporation
1993: Listed On BSE Limited
1996: Amalgamation of Rupal Chemical Industries Limited, Rashesh Chemicals & Pharmaceuticals Limited, Manjarati Chemicals Private Limited, Manjarati Plastisizer Private Limited, Effective Chemicals Private Limited, Star Aluminium Industries Limited and Avez Wire
1998: Turnover of Rs 100 crore
2003: Listed On National Stock Exchange of India Limited
2008: Approval of USFDA Plant
2011: Turnover of Rs 500 crore
2014: Turnover of Rs 1000 crore 100% holdings in Pinnacle Life Science Pvt. Ltd.
2015: Aarti Drugs Limited -PBT More than Rs 100 crore
2017: Rs 100 crore Turnover Pinnacle Life Science Pvt. Ltd. Pinnacle Life Science (Sikkim) Plant ready for operations
2019: Turnover of Rs 1500 crore
2020: Crossed Rs 2000 crore consolidated turnover and Rs 200 crore formulation turnover
2020: Crossed PAT amounted Rs 200 crore
2022: Consolidated revenue Rs 2500 crore